SG11201806496SA - Antigen binding proteins that bind pd-l1 - Google Patents
Antigen binding proteins that bind pd-l1Info
- Publication number
- SG11201806496SA SG11201806496SA SG11201806496SA SG11201806496SA SG11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bind
- january
- pct
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property , Organization MD 1111101110101011111 HO 11111 0111011100101111101110101111111011 III International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/132562 Al 3 August 2017 (03.08.2017) WI P0 I P CT (51) International Patent Classification: C12P 21/08 (2006.01) A61K 39/00 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (21) International Application Number: PCT/US2017/015429 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: ZA, ZM, ZW. 27 January 2017 (27.01.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: 62/288,912 29 January 2016 (29.01.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventor; and SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant : ZHOU, Heyue [CN/US]; 15732 Potomac GW, KM, ML, MR, NE, SN, TD, TG). Ridge Road, San Diego, CA 92127 (US). Published: (74) Agents: HERRITT, Danielle, L. et al.; McCarter & Eng- lish, LLP, 265 Franklin Street, Boston, MA 02110 (US). with international search report (Art. 21(3)) (81) Designated States (unless otherwise indicated, for every before the expiration of the time limit for amending the claims and to be republished in the event of receipt of kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = 1-1 N kr) N M 11 IN 11 © (54) Title: ANTIGEN BINDING PROTEINS THAT BIND PD-L1 el 0 (57) : There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD -L1, PD-L1 -binding fragments that can be manufactured at high- er yields.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662288912P | 2016-01-29 | 2016-01-29 | |
PCT/US2017/015429 WO2017132562A1 (en) | 2016-01-29 | 2017-01-27 | Antigen binding proteins that bind pd-l1 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806496SA true SG11201806496SA (en) | 2018-08-30 |
Family
ID=59386438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806496SA SG11201806496SA (en) | 2016-01-29 | 2017-01-27 | Antigen binding proteins that bind pd-l1 |
Country Status (16)
Country | Link |
---|---|
US (3) | US10118963B2 (en) |
EP (1) | EP3408400A4 (en) |
JP (3) | JP6883590B2 (en) |
KR (1) | KR20190026642A (en) |
CN (2) | CN116333124A (en) |
AU (1) | AU2017212717B2 (en) |
BR (1) | BR112018015480A2 (en) |
CA (1) | CA3013051A1 (en) |
CL (1) | CL2018002034A1 (en) |
EA (1) | EA037855B1 (en) |
IL (1) | IL260846B2 (en) |
MX (2) | MX2018009228A (en) |
PH (1) | PH12018501611A1 (en) |
SG (1) | SG11201806496SA (en) |
TW (1) | TWI760323B (en) |
WO (1) | WO2017132562A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115093480A (en) | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-L1 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EA037855B1 (en) | 2016-01-29 | 2021-05-27 | Сорренто Терапьютикс, Инк. | FULLY HUMAN ANTIBODY OF AN IgG CLASS THAT BINDS TO A PD-L1 EPITOPE |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3768713A2 (en) * | 2018-03-22 | 2021-01-27 | Keires AG | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
CN113121698B (en) * | 2018-04-09 | 2022-11-01 | 原启生物科技(上海)有限责任公司 | anti-PD-L1 antibodies and uses thereof |
WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
KR20210056288A (en) * | 2018-06-01 | 2021-05-18 | 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 | Compositions for treating diseases or conditions and uses thereof |
CN116410320A (en) * | 2018-08-20 | 2023-07-11 | 北京强新生物科技有限公司 | Novel cancer immunotherapeutic antibody compositions |
WO2020215020A1 (en) * | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Humanized anti-pd-l1 antibodies |
CN113795510A (en) * | 2019-08-29 | 2021-12-14 | 荣昌生物制药(烟台)股份有限公司 | anti-PD-L1 antibody and application thereof |
JP2023539369A (en) | 2020-09-02 | 2023-09-13 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Antibody-nanoparticle conjugates and methods of making and using the same |
US20230416369A1 (en) | 2020-11-16 | 2023-12-28 | Immuneoncia Therapeutics, Inc. | Biomarker for predicting therapeutic responsiveness to cancer immunotherapeutic agent and use thereof |
CA3219221A1 (en) | 2021-05-07 | 2022-11-10 | Immuneoncia Therapeutics, Inc. | Bispecific antibody specifically binding to cd47 and pd-l1 |
EP4352100A1 (en) | 2021-06-09 | 2024-04-17 | Sorrento Therapeutics, Inc. | Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JP3051145B2 (en) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | Novel polyethylene glycol derivative modified peptide |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
DE4118120A1 (en) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
JPH05244982A (en) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
JPH07509128A (en) | 1992-07-13 | 1995-10-12 | バイオネブラスカ・インコーポレーテッド | Methods for modifying recombinant polypeptides |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
MX2009012858A (en) | 2007-06-01 | 2010-02-03 | Jackson H M Found Military Med | Vaccine for the prevention of breast cancer relapse. |
US8877688B2 (en) * | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CN115093480A (en) * | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-L1 |
BR112015007672A2 (en) * | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | human monoclonal anti-pd-l1 antibodies and methods of use |
AR093984A1 (en) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN |
WO2014194302A2 (en) * | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
CA2944767C (en) * | 2014-04-04 | 2022-07-12 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
CN105238762A (en) * | 2015-10-26 | 2016-01-13 | 无锡傲锐东源生物科技有限公司 | Anti-PD-1 protein monoclonal antibody hybridomas cell, anti- PD-1 monoclonal antibody generated by same and application |
EA037855B1 (en) * | 2016-01-29 | 2021-05-27 | Сорренто Терапьютикс, Инк. | FULLY HUMAN ANTIBODY OF AN IgG CLASS THAT BINDS TO A PD-L1 EPITOPE |
-
2017
- 2017-01-27 EA EA201891709A patent/EA037855B1/en unknown
- 2017-01-27 US US15/418,514 patent/US10118963B2/en active Active
- 2017-01-27 BR BR112018015480-6A patent/BR112018015480A2/en not_active Application Discontinuation
- 2017-01-27 KR KR1020187024978A patent/KR20190026642A/en active Search and Examination
- 2017-01-27 CN CN202210999239.9A patent/CN116333124A/en active Pending
- 2017-01-27 WO PCT/US2017/015429 patent/WO2017132562A1/en active Application Filing
- 2017-01-27 SG SG11201806496SA patent/SG11201806496SA/en unknown
- 2017-01-27 CN CN201780021396.XA patent/CN109715821B/en active Active
- 2017-01-27 CA CA3013051A patent/CA3013051A1/en active Pending
- 2017-01-27 JP JP2018559164A patent/JP6883590B2/en active Active
- 2017-01-27 MX MX2018009228A patent/MX2018009228A/en unknown
- 2017-01-27 EP EP17745008.7A patent/EP3408400A4/en active Pending
- 2017-01-27 AU AU2017212717A patent/AU2017212717B2/en active Active
- 2017-02-02 TW TW106103519A patent/TWI760323B/en active
-
2018
- 2018-07-27 MX MX2022011659A patent/MX2022011659A/en unknown
- 2018-07-27 CL CL2018002034A patent/CL2018002034A1/en unknown
- 2018-07-29 IL IL260846A patent/IL260846B2/en unknown
- 2018-07-30 PH PH12018501611A patent/PH12018501611A1/en unknown
- 2018-10-10 US US16/156,895 patent/US10919964B2/en active Active
-
2021
- 2021-01-13 US US17/148,450 patent/US11919952B2/en active Active
- 2021-03-22 JP JP2021047470A patent/JP7140867B2/en active Active
-
2022
- 2022-04-15 JP JP2022067548A patent/JP2022095910A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201804694SA (en) | Dual controls for therapeutic cell activation or elimination | |
SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |